Seroepidemiology of hepatitis C virus infection in the Philippines: A preliminary study and comparison with hepatitis B virus infection among blood donors, medical personnel, and patient groups in Davao, Philippines
Seroepidemiology of hepatitis C virus infection in the Philippines: A preliminary study and comparison with hepatitis B virus infection among blood donors, medical personnel, and patient groups in Davao, Philippines
复制标题
菲律宾丙型肝炎病毒感染的血清流行病学：菲律宾达沃市献血者、医务人员和患者群体中乙型肝炎病毒感染的初步研究及比较
DOI：
--
复制
发表时间：
1991
期刊：
影响因子：
--
通讯作者：
Hiroshi Suzuki
中科院分区：
文献类型：
--
作者：
Marilyn O. Arguillas;E. Domingo;F. Tsuda;M. Mayumi;Hiroshi Suzuki
本研究旨在确定菲律宾丙型肝炎病毒的血清阳性率，并将其与从392名献血员、123名医务人员和80名患者中收集的594份血清样本中的B型肝炎病毒感染、HBV和HCV标志物的血清阳性率进行比较肝病45例：急性肝炎25例，肝硬化9例，肝细胞癌11例; 28例B型肝炎携带者和7例慢性肾功能衰竭透析患者）在菲律宾棉兰老岛达沃进行了检查。HBsAg采用RPHA法，抗-HBc采用HI法，抗-HBs采用PHA法，HBsAg亚型、HBeAg和抗-HBe采用EIA法。测定的HCV标志物为通过ELISA（Ortho诊断系统）测定的抗HCV（抗C100 -3）和也通过ELISA测定的抗HCV核心（抗CP 9和/或抗CP 10）。结果显示，抗-HCV阳性9例（2.2%），抗-HCV核心抗体阳性69例（15.4%），HBsAg携带者9例（2.2%），抗-HBs和/或抗-HBc阳性240例（61.3%）（HBsAg携带者除外）。123名医护人员中抗-HCV阳性2例（1.6%），抗-HCV核心抗体阳性11例（8.1%），HBsAg携带者8例（6.5%），抗-HBs和/或抗-HBc阳性81例（65.8%）。11例肝癌患者中5例（45.4%）为HBsAg携带者，2例抗-HCV核心抗体阳性。9例肝硬化患者中2例抗-HCV阳性（1例抗-HCV，1例抗-HCV核心）。如果抗-HCV阳性意味着携带者状态，那么菲律宾达沃献血者的HCV携带率与HBV携带率相同，潜在献血者不仅应筛查HBV，还应筛查HCV，以预防输血相关肝炎。不到50%的肝硬化和肝癌病例有HBV标志物和HCV标志物，但是，当存在时，这些标志物出现在几乎相同的频率; HCV和HBV在棉兰老岛这两种疾病的发病机制中的作用应进一步研究。
SummaryTo determine the seroprevalence of hepatitis C virus in the Philippines and compare it with the seroprevalence of hepatitis B virus infection, HBV and HCV markers in 594 serum samples collected from 392 blood donors, 123 medical and paramedical personnel, and 80 patients (45 liver diseases: 25 acute hepatitis, 9 liver cirrhosis, and 11 hepatocellular carcinoma; 28 hepatitis B carriers, and 7 chronic renal failure patients undergoing dialysis) in Davao, Mindanao Island, Philippines, were examined. HBsAg was determined by RPHA, anti-HBc by HI, anti-HBs by PHA, and HBsAg subtypes, HBeAg, and anti-HBe by EIA. HCV markers determined were anti-HCV (anti-C100-3) by ELISA (Ortho Diagnostic Systems), and anti-HCV core (anti-CP9 and/ or anti-CPIO) also by ELISA. Results showed that 9 (2.2%) blood donors were anti HCV positive; 69 (15.4%) were anti-HCV core positive Nine (2.2%) were HBsAg carriers; 240 (61.3%) were anti-HBs and/or anti-HBc positive (HBsAg carriers excluded from this group). Two of 123 medical and paramedical staff (1.6% ) were anti-HCV positive; 11 (8.1%) were anti-HCV core positive; Eight (6.5%) were HBsAg carriers and 81 (65.8%) anti-HBs and/or anti-HBc positive. Five of 11 (45.4%) hepatocellular carcinoma patients were HBsAg carriers; 2 were anti-HCV core positive. Two of 9 liver cirrhosis patients were antiHCV positive (1 to anti-HCV and the other to anti-HCV core). If anti-HCV positivity means carrier state, then the HCV carrier rate of blood donors in Davao, Philippines is the same as the HBV carrier rate and prospective blood donors should be screened not only for HBV but also for HCV to prevent transfusion-associated hepatitis. Less than 50% of liver cirrhosis and hepatoHCV carcinoma cases have HBV markers and HCV markers but, when present, these markers appear at almost the same frequency; the role of HCV and HBV in the pathogenesis of these 2 diseases in Mindanao should be further investigated.
DOI：
--
发表时间：
1990
期刊：
JAMA : the journal of the American Medical Association
影响因子：
--
作者：
Stevens,CE;Taylor,PE;Pindyck,J;Choo,QL;Bradley,DW;Kuo,G;Houghton,M
通讯作者：
Houghton,M